RxDoctor Payments Data

Kompal Parmar, MD

Family Medicine · Lubbock, TXNPI 1710270988

Payments from drug & device makers

$12,653in general payments, 2019–2025

Across 665 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • GSK$1K
  • Amgen$937
  • AstraZeneca$844
  • Pfizer$531
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$1001%
  • Food & beverage$12,29697%
  • Education$2572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,653 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$287,528
Medicare patients
1,119
Services billed
9,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide153$186,153
OzempicSemaglutide119$131,328
JardianceEmpagliflozin85$97,325
JanuviaSitagliptin Phosphate45$52,931
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$52,473
LinzessLinaclotide73$47,807
EliquisApixaban61$47,782
CreonLipase/Protease/Amylase24$47,710
TymlosAbaloparatide15$44,646
MyrbetriqMirabegron41$31,432
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog59$30,069
TrulicityDulaglutide26$27,398
ZenpepLipase/Protease/Amylase11$22,501
Tresiba Flextouch U-100Insulin Degludec36$18,874
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$16,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,631$213,551179 claims
Novo NordiskOzempic$472$131,328119 claims
AbbVieLinzess, Creon, Namzaric$2,485$103,192109 claims
Boehringer IngelheimJardiance$54$97,32585 claims
MerckJanuvia, Janumet$152$61,44861 claims
GSKTrelegy Ellipta, Breo Ellipta$1,064$59,72590 claims
PfizerEliquis, Premarin$531$58,06380 claims
Radius Health, Inc.Tymlos$396$44,64615 claims
Astellas Pharma US IncMyrbetriq$312$31,43241 claims
AstraZenecaBreztri Aerosphere, Symbicort$844$20,74533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →